Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
Titel:
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
Auteur:
Trauner, Michael Bowlus, Christopher L. Gulamhusein, Aliya Hameed, Bilal Caldwell, Stephen H. Shiffman, Mitchell L. Landis, Charles Muir, Andrew J. Billin, Andrew Xu, Jun Liu, Xiangyu Lu, Xiaomin Chung, Chuhan Myers, Robert P. Kowdley, Kris V.